SRSF2 and myelofibrosis: Considering overall, leukemia-free or myelofibrosis-free survival, ASXL1, SRSF2, and IDH1 mutations were related as “adverse.” Through the use of next-generation sequencing, this work has defined mutations that were associated with poorer overall survival (Tefferi et al., 2016a).